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INTRODUCTION
Cobalamin (Cbl) represents the structurally most 
complex member of the porphyrinoid family. It consists 
of a central cobalt ion, a tetradentate corrin macrocycle, 
a dimethylbenzimidazole (Dmbz) base that is connected 
to the f-side chain of the corrin by a α-ribazole 
containing backbone and an upper, axially coordinating 
ligand (Fig. 1) [1, 2].
MethylCbl (MeCbl) and adenosylCbl (AdoCbl) 
(Fig. 1) are mainly known as organometallic cofactors in 
methyl transfer reactions [1, 2] and radical rearrangements 
[3]. Only recently it has been demonstrated that AdoCbl 
employs even more versatile functions in biological 
systems and acts as a light sensing system in bacteria 
such as Myxococcus xanthus [4, 5]. 
This exciting discovery suggests that other important, 
yet unknown roles of Cbls in biological systems will be 
unraveled in the future [6]. 
Reactivity, properties and functions of Cbls in biological 
systems are related to their intrinsic redox and coordina tion 
properties at the cobalt center and are skillfully fine-tuned 
by the apoenzymes [3]. Cbls are encountered as octahedral 
complexes in the CoIII state, as square pyramidal CoII-, 
or square planar CoI-forms after one- or two-electron 
reductions. In the complexes, the intramolecular bound 
Dmbz base is either coordinated (“base-on”) to the metal 
center or in an unbound configuration (“base-off”). The 
base-on/base-off equilibrium of Cbls (Scheme 1 middle) 
plays important roles for (i) B12 uptake [7], (ii) B12 
metabolism [8] and (iii) cofactor’s reactivity in enzymatic 
reactions [9].
For example, a switch from base-on co(II)balamin to 
its base-off form (Scheme 1) shifts the pH-independent 
standard potential of the CoII/CoI reduction from -0.85 V 
vs. SCE to -0.74 V vs. SCE by ~110 mV more positive 
and hence, reduction is thermodynamically favored 
[10]. This behavior can be explained by the weaker 
σ-donating properties of the aqua ligand compared to 
the intramolecular coordinated Dmbz base in the square 
pyramidal complexes. The thermodynamically more 
accessible base-off co(II)balamin is therefore probably 
encountered during reductive adenosylation with ATP 
to AdoCbl catalyzed by adenosyltransferase in the 
mitochondria [8].
In certain cofactor–protein complexes such as 
MeCbl-dependent methione synthase (MetH) as well as 
AdoCbl-dependent methylmalonyl CoA mutase (MCM), 
the replacement of the intramolecular bound Dmbz 
nucleotide loop of Cbls by a protein’s histidine (His) 
residue is observed [11, 12]. The cobalt-coordinated His 
is further embedded in a hydrogen bonding network, 
together with aspartic acid (Asp) and either lysine (for 
MCM) or serine (for MetH) [13].
This particular mode of cofactor anchoring has 
similarities to His-on coordinated heme proteins in 
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globins, cytochrome c or horseradish peroxidase [14]. In 
these cofactor–protein complexes, partial deprotonation 
of the lower coordinated His-ligand enhances the electron 
density at the iron center and the opposite located axial 
ligand (“push effect”) [15, 16]. In contrast to heme 
proteins, the roles of the lower coordinated protein 
histidine ligand and the hydrogen bonding network 
for catalysis in base-off/His-on Cbl-protein complexes 
have been controversially discussed [17]. Mutation 
studies with MetH revealed a significant decrease of 
enzyme activity when either His or Asp were replaced 
by other amino acids in the hydrogen bond network 
[18]. A more recent study suggested the stabilization 
of a catalytically active Co(II) intermediate in “His-on” 
AdoCbl-dependent isomerases by a less basic His ligand 
[17]. Clearly, further studies on Cbl-protein complexes 
and thoroughly designed model complexes are required 
to better understand the roles and impacts of the first 
and second coordination sphere of Cbls in enzymatic 
reactions.
This short review focuses on the author’s group 
efforts in the development of modified B12 derivatives 
with a peptide backbone as models of cofactor–protein 
complexes as well as for medicinal and biological 
applications. For more comprehensive insight into the 
topic including the uptake, metabolism and reactivity 
of Cbls in biological systems [3, 7, 8, 17, 19–21], the 
development of B12 derivatives as biomimetic models 
[22–28], or the use of Cbls for medical [2, 29–40] and 
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referred to the original literature as well as to several 
excellent reviews and book chapters [2, 3, 8, 47–51].
Modified vitamin B12 derivatives with  
a peptide backbone
In 2010, my group reported on a new class of modified 
B12 derivatives with a peptide backbone containing a 
Dmbz base (Fig. 2b) [52, 53]. This structural motif 
was introduced into the B12 scaffold in order to control 
intramolecular coordination of the Dmbz to the cobalt 
center of the corrinoid. In particular, we speculated that 
pertubation of the base-on/base-off trigger may lead to 
“dysfunctional” B12 analogs with potential antivitamin 
B12 activity [29]. With this general idea in mind, we 
decided to replace the ribose phosphodiester moiety of 
Cbls with peptide mimics having the same number of 
atoms between the corrin macrocycle and the nitrogen 
donor of the Dmbz ligand (Fig. 2b). The peptide mimic 
of the semi-artificial Cbl is attached to the f-side chain of 
the precursor cobyric acid (Fig. 2a) and consists of three 
different subunits: (i) an ethylenediamine, (ii) an amino 
acid and (iii) an acyl modified Dmbz base. The modular 
composition of the peptide linker allows rapid and 
straightforward structural modifications and hence seems 
to be optimally suited for modulating the strength of 
intramolecular coordination in the semi-artificial system.
The structural motif for backbone modification of 
Cbls was inspired by the development and applications of 
peptide nucleic acids (PNAs) which represent powerful 
analogs of deoxyribonucleic acids (DNA) [54]. In the 
prototype peptide B12 derivative 2
+, the peptide loop of 
the compound contains an ethylenediamine and a glycine 
(Fig. 2). 
Similarly to B12, compound 2
+ is present in its base-on 
form at pH 7 and 23 °C, however spectrophotometric pH 
titrations revealed that the base-on form is destabilized 
by a factor of ~20 compared to B12. This property of 2
+ is 
indicated by a pKbase-off value of 1.4 instead of 0.1 for B12 
[12, 52]. Introducing proline as a more rigid u-turn mimic 
instead of glycine into the artificial linker of peptide B12 
4+ (Fig. 2b) led to a three times greater stabilization of the 
base-on form (pKbase-off (4+) = 1.0) compared to 2
+. A remote 
methyl group located at position C176 of the backbone 
caused the most interesting effect in this study. Whereas 
5+ (Fig. 2) with an R-configured methyl group stabilized 
the base-on form by a factor of two (pKbase-off (5+) = 0.6), its 
epimer 6+ (Fig. 2b) showed the opposite behavior and led 
to a significant 10-fold destabilization (pKbase-off (6+) = 1.6). 
This strong effect seems surprising considering that the 
equipment of the backbone with a remote methyl group is 
ten atoms away from the Co ion. Conformational analysis 
of the artificial loop revealed that the methyl group effect 
at C176 is probably best rationalized by an additional 
gauche effect in the base-on form of 6+ compared to 
5+, as schematically depicted in Scheme 2. This type 
of analysis of the backbone of Cbls has been proposed 
earlier by Eschenmoser and later successfully applied by 
Kräutler and co-workers [55, 56]. Although final proof 
for the effect of a remote methyl group in peptide B12s by 
crystal structure analysis of 5+ and/or 6+ is unfortunately 
still lacking, the data suggest that artificial peptide loops 
indeed represent versatile mimics of the α-ribonucleotide 
backbone of B12.
Modifications of the backbone structure in peptide B12s 
had also an influence on the redox properties of the CoIII 
center. In general, it was observed that the more stable the 
base-on form of a peptide B12 derivative, the more difficult 
it was to reduce from CoIII to CoII. Although the effect was 
rather small (∆V = 57 mV), a linear relationship between 
the cathodic reduction potential of the CoIII/II reduction 
and the pKbase-off values was observed [52].
In contrast to modifications at the f-side chain of Cbls, 
we also expanded the concept to peptide mimics of the 
upper adenosyl ligand. PeptidoadenosylCbl 7 (Fig. 3) 
was employed in enzymatic studies with glutamase 
mutate from Clostridium cochlearium as an AdoCbl 
mimic lacking the 2′-OH and 3′-OH functional groups of 
the adenosyl ligand. Although 7 still binds strongly to the 
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Fig. 2. (a) Cobyric acid. (b) The backbone of B12 (1; left) compared to that of peptide B12s (2
+, 3+; middle). Peptide B12s 4
+–6+ are 
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In combination with other control experiments, this 
result underscored the important roles of the 2′-OH and 
3′-OH of the ribose moiety of AdoCbl during generation 
of the Ado radical and hydrogen abstraction from the 
substrate in enzymatic catalysis [57].
Peptide B12 derivatives as antivitamin B12  
derivatives
In the last decade, the development of structurally 
modified B12 derivatives with antivitamin activity has 
regained considerable attention [20, 30, 33, 58, 59]. 
Antivitamins are molecules that diminish or abolish 
specific functions of vitamins [29, 59, 60] potentially 
having future impact as new anticancer and antibiotic 
agents [2].
The impact of structural modification of the backbone 
in peptide B12s on the biological activity of the natural 
product was tested in enzymatic as well as bacterial 
growth studies in my group. The artificial cofactor 3+ 
(Fig. 2) was applied in an enzymatic assay with glutamate 
mutase from Clostridium cochlearium [20]. Similar 
apparent values for the Michaelis–Menten constants of 3+ 
and AdoCbl suggest comparable affinities of the cofactors 
to the enzyme and demonstrate that both cofactors were 
able to reconstitute hologlutamate mutase. The artificial 
cofactor 3+ showed a ten times lower catalytic 
efficacy (kcat/Km = 0.26 × 10
-6 s-1 M-1) compared 
to the natural cofactor AdoCbl (kcat/Km = 2.38 × 
10-6 s-1 M-1). A strongly reduced activity was 
also observed in bacterial growth studies with 
L. leichmannii applying the related cyano-
derivative 2+ (Figs 2 and 4).
A residual growth promoting behavior indic-
ates that despite its severe structural modification, 
2+ is still recognized as Cbl, taken up, metabolized 
and enzymatically active in the microorganism. 
Nevertheless, competition studies with B12 and 2
+ 
demonstrated that peptide B12 2
+ antagonizes the 
natural vitamin with an IC50 value of 2 µM after 
10 h (Fig. 4). 
Considering that only the prototype peptide 
B12 2
+ was tested so far, the results seem to 
be very promising for developing even more 
efficient B12 antivitamins in the future.
Peptide B12 derivatives in biomimetic studies 
His-on cofactor anchoring is observed in base-off/
His-on cofactor B12-protein complexes such as MetH 
[9]. Considering similarities to heme proteins, remote 
control of the lower-coordinated His ligand on reactivity 
at the opposite site seems therefore attractive for fine-
tuning catalysis in cofactor B12-catalyzed reactions [9]. 
In particular, partial deprotonation of the His ligand 
through a protein hydrogen bonding network has been 
proposed to reversibly stabilize and destabilize the CoIII-
state during catalysis [13, 18], but this mechanism is still 
controversially discussed [17, 61].
My group develops and studies homogenous and 
immobilized peptide B12 derivatives as structural 



































Scheme 2. Qualitative conformational analysis of the effect of the methyl 
group at C176 by using idealized conformations around the C175–C176 
bond. Left: ‘Base-on’ B12 (1) with one destabilizing gauche interaction. 
Middle: ‘Base-on’ peptide B12 5
+ with one destabilizing gauche interaction. 
The methyl group at C176 is anti. Right: ‘Base-on’ peptide B12 6
+ with two 





















Fig. 3. Comparison of the structures of AdoCbl and 
peptidoadenosylCbl 7
Fig. 4. Inhibition of growth of L. leichmannii in the presence of 
B12 and peptide B12 2
+ (Inhibition Test) compared to the growth 
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analyzes the influence of lower ligand modulation on the 
properties of the biomimetic model. The latter consists 
of a peptide B12 derivative that is immobilized on a C18 
solid phase (Scheme 3). Peptide B12 8
+ simulates the His-
coordinated cofactor and consists of a corrin macrocycle, 
a peptide loop terminated with a His instead of a Dmbz 
base as lower coordinating ligand, and a cyano group on 
the upper, opposite axial site.
Structural modelling with QM/MM calculations 
supported by characterization with 2D-ROESY NMR 
suggested the imidazole backbone derivative 8+ as a close 
biomimetic model of His-on-configured Cbl-protein 
complexes [62]. Spectrophotometric pH titrations of 8+ 
indicated a pKa for the coordinated imidazole ligand 
of 10.8 (Scheme 4), that is approximately four pH 
units lower than in free imidazole (pKa = 14.5) [63]. 
Cyclovoltammetric studies with 8+ and 8 strikingly 
demonstrated the influence of the deprotonation of 
the nitrogen atom of the coordinated imidazole ligand 
on the redox properties at the CoIII ion. A substantial 
cathodic shift of ~ -200 mV for the CoIII/CoI couple was 
observed upon deprotonation of 8+ to 8. Deprotonation 
of the coordinated His ligand of 8+ leads to a stronger 
σ-donating ligand that shifts more electron density 
to the CoIII ion and hence makes its reduction 
thermodynamically unfavored. Deprotonation of the 
imidazole ligand to a more basic imidazolate is also 
reflected in a bathochromic shift of the α-band in the 
UV-vis spectrum of 8 compared to 8+ as observed for 
Cbls with other axially coordinating ligands [40, 64]. 
Immobilization of 8+ on hydrophobic C18 silica to 
8+SP mimics the hydrophobic binding pocket of proteins 
(Scheme 3). The reflectance spectrum of 8+SP resembled 
that of base-on 8+ under homogenous conditions. The 
addition of toluene, a solvent that lacks any H-bond 
acceptor capability to the system, did not lead to 
any spectral changes. However, addition of benzoate 
(tetrabutylammonium salt) to this solvent then led 
to a slight but characteristic shift in the reflectance 
spectrum. This behavior resembles the spectral changes 
upon (partial) deprotonation of 8+ under homogenous 
conditions and suggests hydrogen bonding between 
benzoate and the intramolecularly bound imidazole 
ligand of 8+SP as schematically depicted in Scheme 3 
(right). These model studies under homogenous and 
heterogeneous conditions strongly suggest that partial 
deprotonation of a coordinated His ligand in Cbl-
protein complexes indeed represents a powerful tool 
to fine-tune the redox chemistry at the Co ion during 
enzymatic catalysis. Having this unprecedented 
supramolecular model in hand, we plan to expand 
the program and study the catalytic activity of 
















































Scheme 3. Left: Cbl bound to the regulatory triad His–Asp–Ser in base-off/His-on Cbl-protein complexes. Right: The corresponding 
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CONCLUSIONS
The development of modified B12 derivatives attracts 
attention for fundamental research, but also for applications 
in medicine, biology, catalysis and analytical science. 
Backbone-modified peptide B12 derivatives with tunable 
coordination and redox properties represent a versatile 
class of Cbls for applications in biology and biomimetic 
chemistry. Pioneering studies with peptide B12 derivatives 
demonstrated promising inhibitory potential and suggest 
medicinal potential as antibacterial and antiproliferative 
agents after further optimization. 
Immobilized supramolecular peptide B12 assemblies 
represent powerful structural models of His-on Cbl-
protein complexes and help to unravel mechanisms in 
B12-catalyzed enzymatic reactions. Evidently, backbone 
modified corrinoids exhibit great potential in different 
fields that have not yet been exploited sufficiently.
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